Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cosmos Health Inc. - Common Stock (NQ:COSM)

0.5190 -0.0185 (-3.44%)
Streaming Delayed Price Updated: 3:42 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cosmos Health Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
Via ACCESS Newswire
News headline image
Cosmos Health is Forcing the Market to Reframe the Conversation
Via ACCESS Newswire
News headline image
Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury Strategy
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
Via ACCESS Newswire
News headline image
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.